Topics: Research and Development, Cancer, Drug Cost
From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
Catalyst-Logo-Featured-Image.jpg.
Since a peak in 1991, cancer mortality rates have declined by as much as 27% around the world. These gains in cancer survival are largely attributed to new and innovative therapies. According to the CDC, for patients with childhood leukemia, prostate, and breast cancers, five-year survival has increased steadily in most developed countries, with some countries reporting five-year survival rates of more than 85%.
New treatments continue to alter the course of previously fatal diseases and there are now more promising cancer medicines in the pipeline than at any time in history. Personalized medicines such as immunotherapy are transforming cancer care in ways never before seen, using patients’ immune systems to fight or eliminate cancers.
To learn more check out our International Cost in Context information.
Topics: Research and Development, Cancer, Drug Cost
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004
Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."